INTRODUCTION
The cytotoxicity of the nucleosides adenosine and 2'-deoxyadenosine may explain the severe combined immune dysfunction in genetic deficiency ofadenosine Dr Received for publication 4 December 1978 and in revised form 8 January 1979. deaminase (ADA,' EC 3.5.4.4) (1) . Adenosinie arrests the growth of huiman lymiphoblast muitctants unable to convert it to adenine nucleotides (2). A high affinity adenosine binding protein, postulated to edieclate this nucleotide-independent toxicity (2) , has beeni identified as the enzyme S-adenosylhomocysteine (AdoHcy) hydrolase (EC 3.3.1.1) (3), which catalyzes the reversible reaction, adenosine + L-homocysteine = AdoHcv. Because the equilibrium constant of this reaction favors AdoHcy fonrmation (4) , loss of ADA can lead to accumulation of AdoHcy (5) , a product and potent inhibitor of numerous S-adenosylmethionine-dependent methvl transfer reactions. Such inhibition of traismethylation appears to account for nucleotide-independent adenosine toxicity to mouse (5) and human lymphoblasts. 2 Hershfield (6) has recently proposed that AdoHcv hydrolase may be a "target" for nucleotide-iindependent effects of 2'-deoxyadenosine, as well as of adenosine, in ADA deficiency. Thus, humclan lyNmphoblast AdoHcy hydrolase was found to bind [3H]2'-deoxyadenosine tightly, and binding was associated with irreversible inactivation of catalytic activity (6) by an active sitedirected, "suicide-like" (7, 8) process. We now wish to report evidence for the operation of this process in vivo-the striking deficiency of AdoHcv hydrolase activity in the erythrocytes of three ADA-deficienit paitienits.
IAbbreviations used in this paper: ADA, adenosine deaminase; AdoHcy, S-adenosylhomocysteine; EHNA, erythro-9-(2-hydroxy-3-nonyl) adenine. 2 Kredich, N. NM., and NI. S. Hershfield. 1979 . S-Adenosvlhomocysteine toxicity in normal and adenosine kinasedeficient lymphoblasts of human origin. Proc Preparations ofcell extracts. Hemolysates were prepared from heparinized blood by mixing packed erythrocytes (washed twice with phosphate-buffered saline at 4°C) with an equal volume of distilled water followed by freezing, thawing, and centrifuging at 9,000 g for 30 min. For high pressure liquid chromatographic analysis, cells and plasma were extracted in HCl04 and neutralized as previously described (5) .
Enzyme assays. AdoHcy hydrolase was assayed by measuring conversion of [8-'4C] adenosine and L-homocysteine to AdoHcy by a thin-layer chromatographic method (3, 6) . Reaction mixtures (0.05 ml) contained 5-20 ,ul of diluted (0-to 20-fold) hemolysate; 25 mM potassium phosphate, pH 7.0; 1 mM dithiothreitol; 1 mM Na2 EDTA; 5 ,uM EHNA; 150 ,uM [8-14C] adenosine (20-40 cpm/pmol); and 5 mM L-homocysteine. The ADA inhibitor, EHNA (9) , was used to prevent rapid catabolism of ['4C]adenosine and(or) 2'-deoxyadenosine and did not interfere with AdoHcy hydrolase activity. Enzyme activity was linear both with time for up to 60 min, and with the hemolysate concentration. Assays were performed in duplicate and for two time points. ADA, adenine phosphoribosyltransferase, hypoxanthine-guanine phosphoribosyltransferase, and adenosine kinase were assayed as previously described (2) .
Protein was assayed by the method of Lowry et al. (10) and hemoglobin as cyanomethemoglobin. High pressure liquid chromatographic measurements were determined using a Waters model 6000 instrument, (Waters Associates, Inc., Milford, Mass.) with a Whatman Partisil SAX column (Whatman, Inc., Clifton, N. J.) for dATP (11) , and a Waters C,8 uBondapak column (Waters Associates, Inc.) for adenosine and 2'-deoxyadenosine. Separation of nucleosides was achieved with 50 mM Na acetate, pH 5.0, containing 5% methanol.
Description of patient. A severely ill 9-wk-old caucasian male was transferred to Duke University Medical Center (Durham, N. C.) with a presumptive diagnosis of severe combined immunodeficiency disease, based upon a 5-wk history of persistent cough, oral moniliasis, failure to thrive, and laboratory data which included a leukocyte count of 5,300 per mm3 with 19% lymphocytes, 38% polys, 3% stabs, 8% monocytes, 32% eosinophils, 1% basophils; and diminished immunoglobulin levels (IgG = 1:10, IgM = 5, and IgA = 5 mg/dl). The diagnosis was confirmed by additional findings of persistent lymphopenia (350-1,000 per mm3) with En rosetting of <2% (normal = 64%); and lack ofblastogenic response ofperipheral blood mononuclear cells to phytohemagglutinin, pokeweed mitogen, or concanavalin A, using methods previously described (12, 13) . ADA deficiency was found in erythrocytes and peripheral mononuclear cells (see Results). Candida albicans meningitis was diagnosed and responded to treatment with 5-fluorocytosine and amphotericin B. Transfusion therapy (14) with fresh irradiated whole blood at a dose of 30 ml/kg at weekly intervals for 4 wk, then biweekly, begun at 10 wk of age had not yet resulted in significant alteration in the patient's immune status.
RESULTS
The pretreatment activities ofAdoHcy hydrolase, ADA, and adenine phosphoribosyltransferase in hemolysates of three unrelated patients are shown in Table I, and the variation in these activities in the Durham patient during a 2-mo period from diagnosis through the initial period ofhypertransfusion are shown in Fig. 1 . All three patients had virtually undetectable ADA activity, and each had <2% of mean control AdoHcy hydrolase activity; adenine phosphoribosyltransferase was within the normal range for this laboratory (Table I) . Activities of hypoxanthine-guanine phosphoribosyltransferase, adenosine kinase, and purine nucleoside phosphorylase were also within the normal range (data not shown). With hypertransfusion, both ADA and AdoHcy hydrolase activities increased in the Durham child's erythrocytes, reflecting the contribution of donor cells (Fig. 1) . However, AdoHcy hydrolase activity did not increase to the extent that would have been expected from the increase in ADA activity. Furthermore, there appeared to be a greater fall in AdoHcy hydrolase than in ADA activity between transfusions. For example, the last set of data in Fig. 1 obtained from the Toronto patient 6 d after a transfusioni had -20% of control AdoHcy hydrolase activity, but ADA activity in the normal range. Inactivation by 2'-deoxyadenosine of AdoHcy hydrolase in a normal adult hemolysate is shown in Fig. 2 . When whole blood from a normnal individual was incubated with 10 ,uM EHNA to inhibit ADA, 10 and 50 ,uM 2'-deoxyadenosine inactivated intracellular AdoHcv hydrolase at initial rates of -4.7 and 13.9%/mim, with 44 and 83% inactivation occurring by 60 min. Slowing of the initial rate of inactivation in intact cells may have resulted at least partly from depletion of inactivator by conversion to intracellular nucleotides, a process which could not occur in the study shown in Fig. 2 . After exposure of whole blood to 10 ,uM [3H]deoxyadenosine for 60 min, followed by lysis and fractionation of the crude hemolysate by gel filtration (as described [6] (6) and erythrocyte AdoHcy hydrolase is associated with irreversible inactivation ofthe enzyme proceeding with first order kinetics, with saturation of the rate of inactivation at high 2'-deoxyadenosine concentration. Inactivation and binding of2'-deoxyadenosine are both prevented by normal enzyme substrates, adenosine and AdoHcy (6) . These findings indicate that inactivation proceeds from an enzyme-2'-deoxyadenosine complex, and suggest an active site directed process which has many characteristics of a suicide process. The latter usually involves covalent attachment of inactivator to enzyme, which does not occur with 2'-deoxyadenosine. Further studies of the mechanism of inactivation are in progress. We believe that prolonged exposure to low concentrations of 2'-deoxyadenosine has led to the in vivo inactivation of AdoHcy hydrolase in the erythrocytes of the patients we have studied. This conclusion is supported by the finding of measurable amounts of the deoxynucleoside in pretransfusion plasma, and by demonstration of rapid inactivation of the enzyme activity in intact normal erythrocytes treated with an ADA inhibitor and 10 ,uM 2'-deoxyadenosine. Impaired deamination of 2'-deoxyadenosine by ADA-deficient patients is also responsible for the striking accumulation of dATP we and others (15) (16) (17) (18) have observed in their circulating blood cells. Because there is continued overexcretion of 2'-deoxyadenosine by ADA-deficient patients despite transftision therapy (18) , continued inactivation by 2'-deoxyadenosine may explain the inability to maintain as high a level of AdoHcy hydrolase as ADA activity by repeated hypertransfusion (Fig. 2) . If this conclusion is correct, then serial measurement of erythrocyte AdoHcy hydrolase activity may be a useful and convenient way to gauge continuing exposure to 2'-deoxyadenosine in ADA deficiency.
We are presently examining factors that determine the degree and effect of AdoHcy hydrolase inactivation in model cell systems. Mature erythrocytes are incapable of new protein synthesis, and therefore are especially susceptible to enzyme inactivation. The relatively slow protein turnover in nondividing, unstimulated lymphocytes might also predispose these cells to develop significant deficiency of AdoHcy hydrolase in ADAdeficient patients. Because AdoHcy hydrolase is the primary AdoHcy catabolizing enzyme in mammalian cells, its nearly complete inactivation should result in accumulation of AdoHcy and inhibition of many transmethylation reactions. Such inhibition might interfere with several essential processes requiring methylation, including, among others, ribosomal RNA maturation, messenger RNA processing, and perhaps membrane function.
The studies reported here and elsewhere (3, 6) establish AdoHcy hydrolase as a target for 2'-deoxyadenosine as well as adenosine (3, 5) toxicity when ADA activity is inhibited or genetically deficient. Further studies will be required to determine the extent to which inactivation of AdoHcy hydrolase contributes to the immume dysfunction in ADA deficiency. However, the disease presents an example of a unique mechanism for production of a secondary enzyme deficiency resulting from a primary inborn metabolic error.
